Children who had already participated in the two-year clinical trial either continued wearing DIMS or switched from the control SV to DIMS. Comparison to an age-matched historical control group showed a myopia control effect in the third year.
The newest myopia controlling spectacles can both correct and control myopia as effectively as contact lens options. How do Defocus Incorporated Multiple Segments (DIMS) and HIghly Aspherical Lenslet Target (H.A.L.T.) technology spectacle lenses work? Here we investigate and compare their design, presumed mechanism and comparative efficacy for myopia control, based on published research.
This study reports one year results from an ongoing randomized clinical trial examining spectacle lenses with highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) technology. The findings showed the HAL lens controlled refractive and axial progression by 60-70% and SAL by 30-40% over the first 12 months.
Providing spectacle correction is one of the cornerstones of primary eye care, and myopia controlling spectacles can both correct and control myopia. Here we explore the current myopia controlling spectacle lenses which have or are being commercialized, for which peer-reviewed publications are available – their design, presumed mechanism and comparative efficacy.
How do you approach communicating with parents about myopia when they reject even standard single vision correction for their child? This is especially concerning given that even a full strength single vision correction is a better choice than under- or un-correction of myopia – for both myopia progression as well as the child’s functional abilities. This clinical problem is more common than you might think, especially in some regions of the world.
Refraction can be challenging in children, and even more so in a complex presentation as for this case. Is this patient a myope or not? When dealing with a complex case of pseudomyopia, antimetropia and latent hyperopia, all in one patient – how should we manage the patient? The answer involves balancing goals to manage ametropia correction, binocular vision function and myopia control.
What do you do when your patient doesn’t respond to your low-dose atropine treatment? This case explores the nuances in navigating management when atropine doesn’t work as well as you might expect.
Here we explore an overview of spectacle prescribing for myopia management – from when to use single vision, to progressive and bifocal designs, new myopia control specific designs, and whether to fully or under-correct.
Given their lower efficacy compared to contact lens options, is the additional cost of a progressive or bifocal spectacle lens worth it for myopia control? This discussion in the Myopia Profile Facebook group explores the options, with links to further reading.
MCS was hesitating fitting OrthoK to a patient who showed inferior corneal steepening. Her main concern was that OrthoK may induce corneal ecstasia/keratoconus in the future and whether there is a link between OrthoK and keratoconus.
